Bariatric Surgery and Pharmacokinetics of Atomoxetine

Bariatric Surgery and Pharmacokinetics of Atomoxetine: BAR-MEDS Atomoxetine

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03460210

Enrollment

Registered

2018-03-09

Start date

2016-11-02

Completion date

2020-03-03

Last updated

2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Morbid

Keywords

Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Atomoxetine hydrochloride

Brief summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on atomoxetine are investigated.

Interventions

DRUGAtomoxetine

Patients are tested for their normal prescription atomoxetine medication

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen

Exclusion criteria

* Having previously undergone resections in the GI-tract

Design outcomes

Primary

Measure	Time frame
Atomoxetine concentration in blood serum (area under curve (AUC))	From baseline to 1 year postoperatively

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026